Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isis Pharmaceuticals and Thomas, McNerney & Partners have announced that the newly created Altair Therapeutics will focus on the discovery, development and commercialization of Isis's antisense drugs to treat asthma and other respiratory conditions.
Subscribe to our email newsletter
Isis has granted an exclusive worldwide license to Altair for the development and commercialization of ISIS 369645, an inhaled inhibitor of the IL-4/IL-13 signaling pathways for the treatment of asthma. Isis and Altair will also be collaborating to discover drugs directed to other promising targets for the treatment of respiratory conditions.
Jeff Jonas, executive vice president of Isis, said: “Our robust antisense technology allows us to continue to discover and validate many more drug candidates than we can advance ourselves. Altair is the most recent example of our satellite company strategy; through this strategy we expand therapeutic applications for antisense drugs while focusing our internal resources in our therapeutic focus areas in cardiovascular and metabolic diseases.”